Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 4/20 | 0.67 |
| ▸ | RAB9A | P51151 | 4/20 | 0.67 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | ACACB | O00763 | 5/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.46 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6873284 | 0.81 | MAPK1 (0.48) | NPC1RAB9AKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL31396772 | 0.81 | NPC1 (0.69) | NPC1RAB9AKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL6881357 | 0.80 | ALDH1A1 (0.54) | NPC1KMT2ASMN1; SMN2MEN1TP53 | |
| SCHEMBL11949543 | 0.79 | RAB9A (0.79) | NPC1RAB9AKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL880676 | 0.79 | RAB9A (0.79) | NPC1RAB9AKMT2ASMN1; SMN2MEN1 | |
| SCHEMBL6247685 | 0.77 | ALOX5 (0.45) | TP53LMNAHPGD | |
| SCHEMBL5847828 | 0.77 | HDAC6 (0.53) | RAB9ASMN1; SMN2LMNAHPGD | |
| SCHEMBL7561990 | 0.74 | NPC1 (0.50) | NPC1RAB9ASMN1; SMN2TP53LMNA | |
| SCHEMBL6263800 | 0.74 | LMNA (0.41) | KMT2ASMN1; SMN2MEN1LMNA | |
| SCHEMBL24283477 | 0.74 | NPC1 (0.63) | NPC1RAB9AKMT2ASMN1; SMN2MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030139401-A9 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL PYRIDINES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | PHARMACIA CORPORATION | 2003-07-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139401-A9 | SUBSTITUTED POLYCYCLIC ARYL AND HETEROARYL PYRIDINES USEFUL FOR SELECTIVE INHIBITION OF THE COAGULATION CASCADE | TFPI, F2, PLAT | NPC1 3000/4885RAB9A 3104/4885KMT2A 3534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.